Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
Oculis Holding AG has announced a strategic partnership with the National Multiple Sclerosis Society’s Campaign to End MS, focusing on accelerating research and treatment innovations for vision impairments related to MS. Oculis is developing Privosegtor, a novel neuroprotective therapy aimed at optic neuritis and acute MS relapses, currently advanc…